Brief Report: Frailty and HIV Disease Severity Synergistically Increase Risk of HIV-Associated Neurocognitive Disorders.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
15 08 2020
15 08 2020
Historique:
entrez:
22
7
2020
pubmed:
22
7
2020
medline:
12
3
2021
Statut:
ppublish
Résumé
Frailty disproportionally affects people with HIV (PWH) and increased frailty in this already vulnerable population is associated with worse neurocognitive functioning. Whether frailty interacts with current and modifiable markers of HIV disease severity to synergistically increase risk for HIV-associated neurocognitive disorders (HAND), however, is unknown and important for informing the clinical care of aging PWH. UC San Diego's HIV Neurobehavioral Research Program. Participants were 178 PWH evaluated between 2014 and 2019. HIV disease severity was measured by current CD4 count and plasma HIV RNA. HAND diagnoses were made according to the Frascati criteria using a 7-domain neuropsychological battery, and the Fried phenotype criteria were used to assess frailty syndrome (0-5 symptoms). The independent and interactive effects of frailty and current HIV disease severity (ie, CD4 count and plasma HIV RNA) on HAND were examined using multiple logistic regressions. There was an interaction between CD4 count and frailty on HAND. Simple slopes showed that CD4 count and the likelihood of HAND were negatively associated at >1.25 symptoms of frailty, and conversely, frailty and HAND were negatively associated at 642 or less cells/mm. There were no significant independent or interactive effects of plasma HIV RNA and frailty on the likelihood of HAND. In addition to monitoring CD4 count, assessing for frailty may be critical in older adults with HIV to potentially mitigate poor neurobehavioral outcomes. Longitudinal follow-up studies are needed to determine the directionality of these findings.
Sections du résumé
BACKGROUND
Frailty disproportionally affects people with HIV (PWH) and increased frailty in this already vulnerable population is associated with worse neurocognitive functioning. Whether frailty interacts with current and modifiable markers of HIV disease severity to synergistically increase risk for HIV-associated neurocognitive disorders (HAND), however, is unknown and important for informing the clinical care of aging PWH.
SETTING
UC San Diego's HIV Neurobehavioral Research Program.
METHODS
Participants were 178 PWH evaluated between 2014 and 2019. HIV disease severity was measured by current CD4 count and plasma HIV RNA. HAND diagnoses were made according to the Frascati criteria using a 7-domain neuropsychological battery, and the Fried phenotype criteria were used to assess frailty syndrome (0-5 symptoms). The independent and interactive effects of frailty and current HIV disease severity (ie, CD4 count and plasma HIV RNA) on HAND were examined using multiple logistic regressions.
RESULTS
There was an interaction between CD4 count and frailty on HAND. Simple slopes showed that CD4 count and the likelihood of HAND were negatively associated at >1.25 symptoms of frailty, and conversely, frailty and HAND were negatively associated at 642 or less cells/mm. There were no significant independent or interactive effects of plasma HIV RNA and frailty on the likelihood of HAND.
CONCLUSIONS
In addition to monitoring CD4 count, assessing for frailty may be critical in older adults with HIV to potentially mitigate poor neurobehavioral outcomes. Longitudinal follow-up studies are needed to determine the directionality of these findings.
Identifiants
pubmed: 32692111
doi: 10.1097/QAI.0000000000002391
pii: 00126334-202008150-00011
pmc: PMC8667611
mid: NIHMS1761393
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
522-526Subventions
Organisme : NIAAA NIH HHS
ID : F31 AA027198
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH099987
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031098
Pays : United States
Références
Top Antivir Med. 2011 Nov;19(4):137-42
pubmed: 22156215
J Gerontol A Biol Sci Med Sci. 2007 Nov;62(11):1279-86
pubmed: 18000149
J Frailty Aging. 2014;3(3):158-65
pubmed: 27050062
AIDS Patient Care STDS. 2013 Jan;27(1):5-16
pubmed: 23305257
Curr HIV/AIDS Rep. 2014 Sep;11(3):279-90
pubmed: 24966138
Clin Infect Dis. 2011 Dec;53(11):1120-6
pubmed: 21998278
J Am Geriatr Soc. 2014 Nov;62(11):2118-24
pubmed: 25370593
J Am Geriatr Soc. 2016 May;64(5):1006-14
pubmed: 27225356
Annu Rev Med. 2011;62:141-55
pubmed: 21090961
Lancet Neurol. 2019 Feb;18(2):177-184
pubmed: 30663607
J Neurovirol. 2020 Apr;26(2):168-180
pubmed: 31858484
Front Psychol. 2017 Jul 28;8:1293
pubmed: 28804471
Curr HIV/AIDS Rep. 2016 Dec;13(6):340-348
pubmed: 27549318
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
AIDS. 2011 Sep 10;25(14):1747-51
pubmed: 21750419
Neuropsychology. 2019 Mar;33(3):370-378
pubmed: 30816783
Neurology. 2018 Jul 10;91(2):e162-e170
pubmed: 29875216
J Assoc Nurses AIDS Care. 2020 May-Jun;31(3):290-300
pubmed: 31789684
AIDS Patient Care STDS. 2019 Mar;33(3):93-103
pubmed: 30844304
Neurology. 2010 Dec 7;75(23):2087-96
pubmed: 21135382
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
AIDS Behav. 2014 Jun;18(6):1186-97
pubmed: 24633788